We offer two innovative collection tubes. First of which we have developed a unique DNA/RNA transport and storage medium that immediately inactivates the viruses ensuring safety of your laboratory personnel.  viRNAtrap™ Collection Tubes preserve the genetic integrity of samples at ambient temperature for weeks. Second of which is RESALIVA™ utilises an absorption sponge to collect saliva samples which is easy-to-use, pain-free, and comfortable.

Our fast and robust nucleic acid extraction is based on magnetic beads technology. viRNAtrap™ CE-IVDR Extraction Kit can be used for manual and automated nucleic acid purification on any open platform. The kit consists of 4 bottles not requiring controlled temperature storage. The isolation process takes 10 minutes only and enables true high-throughput extraction. The kit is CE-IVDR certified. 

We have developed a high-quality PCR kit for rapid COVID-19 detection. The protocol is designed for about 60 minutes run time that allows laboratories to deliver the results much faster to patients and doctors. Our break-trough triplex PCR kit of COVID-INFA-INFB will provide fast confirmation of the infection type. All kits are CE IVD certified.

GeneSpector offers a groundbreaking method for predicting pregnancy-related complications by analyzing blood samples during the first trimester (10th-13th week). This approach effectively predicts conditions like preeclampsia, fetal growth restriction, preterm birth, and gestational hypertension, significantly improving early intervention and prenatal care. It also identifies undiagnosed chronic hypertension, a key risk factor for complications, offering a high success rate in managing and preventing severe maternal and fetal outcomes.

A next-generation nucleic acid sequencing solution for various diagnostic applications feasible in any laboratory. Currently developing a kit for diagnosing multiple myeloma, a malignant bone marrow disorder, this innovative approach uses a custom set of oligonucleotides in a well-defined NGS panel followed by bioinformatics analysis to determine the disease cause directly. We also offer custom development of sequencing kits for other genetic-based disorder diagnostics and research.

A diagnostic method predicting the severity of infectious disease symptoms days in advance. Using PCR-based detection of specific biomarkers in nasopharyngeal swabs, it identifies high-risk patients early, enabling timely therapy. Applicable to viral, bacterial, and fungal infections, it also monitors treatment efficacy. Optimized for large-scale testing. To develop the methodology and deliver a certified and proven test, GeneSpector decided to found a spin-off company called SeveriDx (www.severidx.com).

A reliable, simple diagnostic solution for hereditary kidney disease ADTKD (Autosomal Dominant Tubulo-Interstitial Kidney Disease). Utilizing a specially developed ELISA-based method to detect the MUC1 protein in blood plasma, this cost-effective technique allows for comprehensive screening and monitoring of disease progression and therapy efficiency. Optimized for large-scale testing, this method provides an accessible alternative to expensive genetic testing and aims to be certified and marketed under a license-based collboration for a global use. 

In collaboration with the company Affipro, we have initiated the development of a 3-D printed single-use device called sample target plate. They are currently used for the method called Microbe MALDI Biotyping, which is applied in clinical microbiology for the identification of pathogens without the need for time-consuming microbial growth in expensive selective media. Using nanotechnologies developed at IQS nano, we have already prepared new prototypes of these target plates, which exhibit good performance for MALDI Biotyping. They may represent a cost-effective and versatile alternative compared to the currently available equipment produced by traditional technologies.

Imagine a world where clinical diagnostics is done with nothing but a simple card. GeneSpector offers a groundbreaking solution using passive chips with nanofluidic structures for complex sample work-up, analyte detection, and result visualization. This method, executable anywhere—even in field conditions—provides robust, fast results with a simple readout at a low price. Applicable for diagnosing conditions like myocardial infarction and infectious diseases, it requires only a drop of a biological sample (e.g., blood, saliva, urine). To develop the technology, GeneSpector in collaboration with IQS Group decided to found a spin-off company in 2024 called Lab On Card (www.laboncard.com).